Eli Lil­ly is mak­ing a $1.8B leap in­to the mR­NA field, tar­get­ing next-gen can­cer vac­cines

Eli Lil­ly is div­ing in­to the mes­sen­ger RNA are­na, sign­ing off on a heav­i­ly back-end­ed $1.8 bil­lion deal with Ger­many’s Cure­Vac to de­vel­op up to 5 new-wave can­cer vac­cines.

Cure­Vac is get­ting $100 mil­lion in cash to kick off the col­lab­o­ra­tion, split be­tween an up­front pay­ment and eq­ui­ty stake. Then there’s a pack­age of $1.7 bil­lion in mile­stones on the ta­ble.

In turn Cure­Vac will be tasked with de­sign­ing a slate of new can­cer vac­cines that us­es mR­NA tech to in­struct the hu­man im­mune sys­tem to tar­get a spe­cif­ic set of neoanti­gens. While past can­cer vac­cines have gen­er­al­ly proven to be in­ef­fec­tive though safe, a num­ber of de­vel­op­ers have been hunt­ing down spe­cif­ic pa­tient anti­gens that can be lever­aged for much more pre­cise tar­get­ing — with a greater like­li­hood of suc­cess.

In­g­mar Ho­err

Cure­Vac, though, has met with a key fail­ure on the can­cer vac­cine ear­li­er in the year. Its lead­ing mR­NA pro­gram CV9104, a prostate can­cer vac­cine, failed a crit­i­cal Phase IIb study in Jan­u­ary. That drug used a group of “shared” anti­gens com­mon to prostate can­cer, while ri­val Mod­er­na has been go­ing af­ter a more per­son­al­ized ap­proach in its pro­gram, part­nered with Mer­ck.

Cure­Vac — backed by Ger­man bil­lion­aire Di­et­mar Hopp along with ad­di­tion­al fund­ing from the Gates Foun­da­tion — is one of the lead­ers in the mR­NA field, with Mod­er­na and oth­ers en­gaged in a sci­en­tif­i­cal­ly de­mand­ing ap­proach to in­struct­ing tar­get­ed cells to cre­ate a treat­ment. It’s still ear­ly days, though we are be­gin­ning to see more ear­ly hu­man da­ta that un­der­scores the po­ten­tial of the field.

For Lil­ly, this is an­oth­er ex­am­ple of a more ex­pan­sive ap­proach to part­ner­ing and ex­ter­nal in­no­va­tion, with new CEO Dave Ricks more like­ly to reach out to col­lab­o­ra­tors than his pre­de­ces­sor John Lech­leit­er.

Not­ed Cure­Vac CEO In­g­mar Ho­err:

This new col­lab­o­ra­tion with Lil­ly is a tes­ti­mo­ny to the progress and so­phis­ti­ca­tion of Cure­Vac’s RN­Ac­tive tech­nol­o­gy and the po­ten­tial of mR­NA-based ther­a­peu­tics. We now have the op­por­tu­ni­ty to com­bine forces to fur­ther ex­pand the ex­cit­ing space of im­muno-on­col­o­gy with the next gen­er­a­tion of can­cer ther­a­pies.


The Eli Lil­ly and Co cor­po­rate head­quar­ters is pic­tured April 26, 2017, in In­di­anapo­lis. AP Pho­to/Dar­ron Cum­mings

Im­ple­ment­ing re­silience in the clin­i­cal tri­al sup­ply chain

Since January 2020, the clinical trials ecosystem has quickly evolved to manage roadblocks impeding clinical trial integrity, and patient care and safety amid a global pandemic. Closed borders, reduced air traffic and delayed or canceled flights disrupted global distribution, revealing how flexible logistics and supply chains can secure the timely delivery of clinical drug products and therapies to sites and patients.

Pascal Soriot (AP Images)

UP­DAT­ED: As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Vas Narasimhan, Novartis CEO (Jason Alden/Bloomberg via Getty Images)

Vas Narasimhan's 'Wild Card' drugs: No­var­tis CEO high­lights po­ten­tial jack­pots, as well as late-stage stars, in R&D pre­sen­ta­tion

Novartis is always one of the industry’s biggest R&D spenders. As they often do toward the end of each year, company execs are highlighting the drugs they expect will most likely be winners in 2021.

And they’re also dreaming about some potential big-time lottery tickets.

As part of its annual investor presentation Tuesday, where the company allows investors and analysts to virtually schmooze with the bigwigs, Novartis CEO Vas Narasimhan will outline what he thinks are the pharma’s “Wild Cards.” The slate of five experimental drugs are those that Novartis hopes can be high-risk, high-reward entrants into the market over the next half-decade or so, and cover a wide range of indications.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

Pur­due Phar­ma pleads guilty in fed­er­al Oxy­Con­tin probe, for­mal­ly rec­og­niz­ing it played a part in the opi­oid cri­sis

Purdue Pharma, the producer of the prescription painkiller OxyContin, admitted Tuesday that, yes, it did contribute to America’s opioid epidemic.

The drugmaker formally pleaded guilty to three criminal charges, the AP reported, including getting in the way of the DEA’s efforts to combat the crisis, failing to prevent the painkillers from ending up on the black market and encouraging doctors to write more painkiller prescriptions through two methods: paying them in a speakers program and directing a medical records company to send them certain patient information. Purdue’s plea deal calls for $8.3 billion in criminal fines and penalties, but the company is only liable for a fraction of that total — $225 million.

John Maraganore, Alnylam CEO (Scott Eisen/Bloomberg via Getty Images)

UP­DAT­ED: Al­ny­lam gets the green light from the FDA for drug #3 — and CEO John Maraganore is ready to roll

Score another early win at the FDA for Alnylam.

The FDA put out word today that the agency has approved its third drug, lumasiran, for primary hyperoxaluria type 1, better known as PH1. The news comes just 4 days after the European Commission took the lead in offering a green light.

An ultra rare genetic condition, Alnylam CEO John Maraganore says there are only some 1,000 to 1,700 patients in the US and Europe at any particular point. The patients, mostly kids, suffer from an overproduction of oxalate in the liver that spurs the development of kidney stones, right through to end stage kidney disease.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,100+ biopharma pros reading Endpoints daily — and it's free.

PhRMA sues Trump gov­ern­ment over drug im­por­ta­tion rule — days be­fore it's set to be ef­fec­tive

Ever since President Donald Trump floated the idea of using state-sponsored importation to lower drug prices, PhRMA has made its opposition abundant. Not only is the proposal dangerous and futile,  but the trade group has also argued that it may even be illegal.

Now that the FDA has issued its final rule permitting states to bring certain drugs from Canada, PhRMA is taking the government to court — just a few days before the rule is slated to take effect.

The ad­u­canum­ab co­nun­drum: The PhI­II failed a clear reg­u­la­to­ry stan­dard, but no one is cer­tain what that means any­more at the FDA

Eighteen days ago, virtually all of the outside experts on an FDA adcomm got together to mug the agency’s Billy Dunn and the Biogen team when they presented their upbeat assessment on aducanumab. But here we are, more than 2 weeks later, and the ongoing debate over that Alzheimer’s drug’s fate continues unabated.

Instead of simply ruling out any chance of an approval, the logical conclusion based on what we heard during that session, a series of questionable approvals that preceded the controversy over the agency’s recent EUA decisions has come back to haunt the FDA, where the power of precedent is leaving an opening some experts believe can still be exploited by the big biotech.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

The flu virus (CDC)

Roche tacks on an­oth­er Xofluza in­di­ca­tion as flu sea­son meets pan­dem­ic

Xofluza was heralded as the first new flu drug in 20 years when it got the FDA OK back in 2018. But even so, Roche saw tough competition from cheaper Tamiflu generics that appeared to be nearly as — if not just as — effective.

Now, the pharma says the drug also can be used to prevent influenza after exposure, snagging a new approval and adding to Xofluza’s appeal as flu season meets the pandemic.

A poll sug­gests vac­cine da­ta boost­ed Pfiz­er's pub­lic im­age, but oth­er da­ta point to long road ahead

For much of the pharmaceutical industry, the pandemic presented an opportunity: to prove their value to the world and turn public opinion around on a business much of the country had come to disdain.

That theory — that helping pull the country from a pandemic could neutralize years of anger over high drug prices — was put to its biggest test this month, as three different drugmakers announced data from their Covid-19 vaccines, offering the first major evidence that industry-built inoculations could turn the tide of the outbreak in the US.